NCT04374136Phase 3Terminated

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Study sponsor: Alector Inc. · ALEC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-01Actual
Enrollment · participants119Actual
Source updated2026-09-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB. After: Measure: Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients Measure: Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients Measure: Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 110 participants (planned). After: 119 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview